Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
ANAVEX LIFE SCIENCES CORP. AVXL

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 2, 2026 8-K 2 signals fired
Other
Nasdaq Minimum Bid Price Delisting Notice Nyse Listing Disclosure
Aug 28, 2026 10-Q 44 signals fired · top 15
Other
Litigation Defense Assertion Material Weakness In Internal Controls Disclosed Net Loss Reported Director Continuity Stated Capital Raising Uncertainty Disclosed Equity Plan Share Reserve Disclosure Personnel Cost Decrease Disclosure Restrictive Debt Covenants Disclosure Nasdaq Minimum Bid Price Delisting Notice Fast Track Designation Received Patent Family Portfolio Disclosure Fast Track Granted
Core
Regulatory Designation Only
Biotech Risk
Trial Endpoint Missed Orphan Drug Designation
Aug 28, 2026 10-Q 30 signals fired · top 15
Other
Change Of Control Definition Net Loss Reported Arbitrator Selection Procedure Liquidity Position Snapshot Disclosed Nasdaq Minimum Bid Price Delisting Notice Equity Plan Share Reserve Disclosure Director Officer Indemnification Provision Cause For Termination Defined Fast Track Designation Received Stock Option Intrinsic Value Disclosure Fast Track Granted Stock Option Grant Disclosed Other Income Expense Disclosure Survival Of Representations Warranties Clause
Core
Regulatory Designation Only
Aug 25, 2026 8-K 13 signals fired
Other
Liquidity Position Snapshot Disclosed Protocol Amended Net Loss Reported Forward Looking Statement Definition Personnel Cost Decrease Disclosure Enrollment Ahead Of Schedule Expanded Access Program Active
Core
Indication Expansion Lead Asset Progress Clinical Hold Clinical Trial Result
Biotech Risk
Clinical Hold Active Crl Received
Aug 11, 2026 8-K 9 signals fired
Core
Lead Asset Progress Indication Expansion Management Exodus
Other
Merger Proxy Statement Disclosure Nasdaq Minimum Bid Price Delisting Notice Stockholder Engagement Disclosure Activist Board Representation Demand Board Diversity Policy Disclosed Fast Track Designation Received
Aug 3, 2026 8-K 10 signals fired
Other
Board Diversity Policy Disclosed Forward Looking Statement Definition Merger Proxy Statement Disclosure Board Committee Composition Disclosure Stockholder Engagement Disclosure Executive Transition Gratitude Statement Fda Aligned
Core
Indication Expansion Lead Asset Progress Management Exodus
Jul 30, 2026 8-K 12 signals fired
Other
Net Loss Reported Revenue Decline Explanation Liquidity Position Snapshot Disclosed Personnel Cost Decrease Disclosure Administrative Efficiency Gene Therapy Aav Operating Margin Declining Forward Looking Statement Definition
Core
Lead Asset Progress Indication Expansion
Biotech Risk
Trial Endpoint Missed
Business Services
Demand Softening
Jul 20, 2026 8-K 1 signal fired
Other
Nasdaq Minimum Bid Price Delisting Notice
May 22, 2026 8-K 2 signals fired
Other
Nasdaq Minimum Bid Price Delisting Notice Nyse Listing Disclosure
May 15, 2026 8-K 1 signal fired
Other
Executive Severance Change Of Control
May 6, 2026 8-K 4 signals fired
Other
Executive Educational Background Disclosure
Core
Management Exodus Indication Expansion Lead Asset Progress
Mar 25, 2026 8-K 12 signals fired
Core
Lead Asset Progress Indication Expansion Clinical Trial Result Clinical Hold
Other
Interim Data Positive Fast Track Designation Received Fast Track Granted Orphan Status Granted Publication Positive Enrollment Ahead Of Schedule Expanded Access Program Active Breakthrough Therapy Granted